PE anti-human CD340 (erbB2/HER-2) Antibody
- 产品名称：
- PE anti-human CD340 (erbB2/HER-2) Antibody
- 产品类别：
- 抗体
- 产品编号：
- 324405
- 产品应用：
- 324405
[价格]
| 规格 |
价格 |
库存 |
| 25tests |
￥ 1608 |
1 |
- Verified Reactivity
- Human
- Antibody Type
- Monoclonal
- Host Species
- Mouse
- Immunogen
- NIH-3T3 transfected with human HER-2
- Formulation
- Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
- Preparation
- The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
- Concentration
- Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
- Storage & Handling
- The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
- Application
-
FC - Quality tested
- Recommended Usage
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood.
- Excitation Laser
- Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
- Application References
(PubMed link indicates BioLegend citation) -
- Bühring HJ, et al. 1995. Blood 86:1916.
- Product Citations
-
- Zhang C, et al. 2015. J Natl Cancer Inst. 108: djv375. PubMed
- Lange T, et al. 2011. Cancer Lett. 308:54. PubMed
- Kazemi S, et al. 2020. Biochem Pharmacol. 114317:183. PubMed
- Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
- Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed
- Vishnoi M, et al. 2015. Sci Rep. 5: 17533. PubMed
- Skidmore L, et al. 2020. Mol Cancer Ther. 19:1833. PubMed
- Pahuja KB et al. 2018. Cancer cell. 34(5):792-806 . PubMed
- Baldassarre T, Truesdell P, and Craig A. 2017. Breast Cancer Res.. 10.1186/s13058-017-0900-z. PubMed
- Castagnoli L, et al. 2016. Oncogene. 10.1038/onc.2016.338. PubMed
- MESCHENMOSER K, et al. 2013. In Vivo. 27:431. PubMed
- Li Z, et al. 2010. J Virol Methods. 169:87. PubMed
- Quijano-Rubio A, et al. 2022. Nat Biotechnol. Online ahead of print. PubMed
- RRID
- AB_756121 (BioLegend Cat. No. 324405) AB_756122 (BioLegend Cat. No. 324406)
- Structure
- Member of the epidermal growth factor receptor family of cell membrane tyrosine kinases. Single transmembrane pass protein with an approximate molecular weight of 185 kD. Contains three furin repeats and two cheY homologous receiver domains in the ECR.
- Distribution
-
Expressed on many tumor cells including some breast cancers, lung adenocarcinoma, gastric cancer, ovarian cancer, gliblastoma, some c-ALL blasts and bone marrow MSCs.
- Function
- Contains no ligand binding domain and interacts with other EGF receptor family members to form a heterodimer, stabilize ligand binding, and enhance kinase-mediated downstream signaling. Involved in embryonic development and cancer progression.
- Interaction
- CD340 (HER2/erbB2) interacts with a large number of proteins, including SHC1, EGF receptorm, neuroregulin 1, c-Src, integrin β4, Grb2, Grb7, SOS1, caveolin 1, JAK2, PAK1, FAK, and β-catenin, among others.
- Modification
- Extensively modified by tyrosine phosphoryation on multiple residues (Y1023, Y1139, Y1196, Y1221, Y1222, Y1248).
- Cell Type
- Leukemia
- Biology Area
- Cell Biology, Immunology, Neuroscience, Synaptic Biology
- Molecular Family
- Adhesion Molecules, CD Molecules
- Antigen References
-
1. Akiyama T, et al. 1986. Science 232:1644.
2. Bargmann CI, et al. 1986. Nature 319:226.
3. Pegram MD, et al. 1997. Oncogene 15:537.
4. Slamon DJ, et al. 1989. Science 244:707.
5. Leone F, et al. 2003. J. Leukocyte Biol. 74:593.
- Gene ID
- 2064 View all products for this Gene ID
- UniProt
- View information about CD340 on UniProt.org
